Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Rhea-AI Summary

Abeona Therapeutics (Nasdaq: ABEO) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference in Miami, Florida. The company's CEO, Vish Seshadri, Ph.D., M.B.A., will deliver a presentation on Monday, March 10, 2025, at 3:00 p.m. Eastern Time.

Investors and interested parties can access a live webcast of the presentation through the 'Events' section of Abeona's investor relations website at https://investors.abeonatherapeutics.com/events. The presentation recording will remain available for replay on the website for 30 days following the event.

CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., will present at the Leerink Partners Global Healthcare Conference in Miami, Florida on Monday, March 10, 2025 at 3:00 p.m. Eastern Time.

A live webcast of the presentation can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 30 days.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of the FDA’s review of our BLA resubmission for pz-cel; the FDA’s grant of a Priority Review Voucher upon pz-cel approval; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

FAQ

When and where will Abeona Therapeutics (ABEO) present at the Leerink Partners Conference 2025?

Abeona Therapeutics will present on March 10, 2025, at 3:00 p.m. Eastern Time in Miami, Florida.

How can investors watch Abeona's (ABEO) Leerink Partners Conference presentation?

Investors can watch via live webcast on Abeona's website under 'Events' at investors.abeonatherapeutics.com/events

How long will ABEO's Leerink Conference presentation recording be available?

The webcast recording will be archived and available for 30 days after the presentation.

Who will represent Abeona Therapeutics (ABEO) at the 2025 Leerink Partners Conference?

CEO Vish Seshadri, Ph.D., M.B.A., will present on behalf of Abeona Therapeutics.